Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integrated Histopathologic and Targeted Genomic Characterization of Gastric Adenocarcinomas with Yolk Sac Tumor Differentiation.

International journal of molecular sciences·2026

Same author

Validated Automated Cuff Blood Pressure Devices for Children: STRIDE BP Report and Call to Action.

Hypertension (Dallas, Tex. : 1979)·2026

Same author

Prognosis Prediction and Shared Decision Making for Personalised Anticoagulant Therapy after Unprovoked Venous Thromboembolism: The MORPHEUS project.

Thrombosis and haemostasis·2026

Same author

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Central Systolic Blood Pressure and Left Ventricular Mass: Findings From the International 24-Hour Aortic Blood Pressure Consortium.

Journal of the American Heart Association·2026

Same author

Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.

Science translational medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade.

Andriani Charpidou¹, Grigorios Gerotziafas², Sanjay Popat³

¹Third Department of Internal Medicine and Laboratory, Athens Medical School, National and Kapodistrian University of Athens, Sotiria General Hospital, 157 72 Athens, Greece.

|January 26, 2024

Summary

Cancer-associated thrombosis (CAT) is a frequent complication in lung cancer patients, with newer treatments potentially increasing risk. Management involves personalized anticoagulation therapy based on individual patient factors and cancer characteristics.

Keywords:

anticoagulation cancer-associated thrombosis immune checkpoint inhibitor lung cancer venous thromboembolism

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Experiment Videos

Last Updated: Jul 4, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Area of Science:

Oncology
Hematology
Pulmonary Medicine

Background:

Cancer-associated thrombosis (CAT) is a significant complication in lung cancer patients.
Lung cancer patients face a higher thrombosis risk than those with other solid tumors.
Emerging therapies like immunotherapy may elevate CAT risk.

Purpose of the Study:

To review the epidemiology, pathophysiology, and risk factors of CAT in lung cancer.
To discuss novel risk-assessment models and management strategies for CAT.
To focus on CAT in the context of immune checkpoint inhibitors and the COVID-19 pandemic.

Main Methods:

Literature review of epidemiology, pathophysiology, risk factors, and management of CAT.
Analysis of risk-assessment models including Khorana Risk Score and genetic factors.
Evaluation of treatment outcomes from prospective trials comparing anticoagulation agents.

Main Results:

Lung cancer significantly increases thrombosis risk across all disease stages.
Low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs) show comparable efficacy in ambulatory patients.
Personalized anticoagulation is crucial, considering cancer specifics and treatments.

Conclusions:

Effective management of CAT requires personalized anticoagulation strategies.
Risk stratification and novel predictive scores aid in managing thrombosis in lung cancer.
Understanding CAT in the era of novel therapies and pandemics is essential.